NEW YORK (GenomeWeb News) – Labcyte said today that it is collaborating with AstraZeneca on applying its acoustic liquid handling technology to mass spec-based drug discovery work.

The collaboration will focus on using Labcyte's technology for direct loading of samples into mass spectrometers, which, the company said, could enable high-throughput, low-cost, label-free mass spec analyses. AstraZeneca aims via the project to expand such mass spec analyses throughout its entire drug discovery and development process.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.